A new agent for the treatment of noninfectious uveitis: rationale and design of three LUMINATE (Lux Uveitis Multicenter Investigation of a New Approach to Treatment) trials of steroid-sparing voclosporin

Eddy Anglade1, Launa J Aspeslet2, Sidney L Weiss11Lux Biosciences Inc., Jersey City, NJ, USA; 2Isotechnika Inc., Edmonton, AB, CanadaAbstract: Uveitis is an inflammatory, putative Th1-mediated autoimmune disease that affects various parts of the eye and is a leading cause of visual loss. Currently a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Eddy Anglade, Launa J Aspeslet, Sidney L Weiss
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/801e6176649a4aa99f9d6d2511d1be30
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:801e6176649a4aa99f9d6d2511d1be30
record_format	dspace
spelling	oai:doaj.org-article:801e6176649a4aa99f9d6d2511d1be302021-12-02T06:17:55ZA new agent for the treatment of noninfectious uveitis: rationale and design of three LUMINATE (Lux Uveitis Multicenter Investigation of a New Approach to Treatment) trials of steroid-sparing voclosporin1177-54671177-5483https://doaj.org/article/801e6176649a4aa99f9d6d2511d1be302008-12-01T00:00:00Zhttp://www.dovepress.com/a-new-agent-for-the-treatment-of-noninfectious-uveitis-rationale-and-d-a2760https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Eddy Anglade1, Launa J Aspeslet2, Sidney L Weiss11Lux Biosciences Inc., Jersey City, NJ, USA; 2Isotechnika Inc., Edmonton, AB, CanadaAbstract: Uveitis is an inflammatory, putative Th1-mediated autoimmune disease that affects various parts of the eye and is a leading cause of visual loss. Currently available therapies are burdened with toxicities and/or lack definitive evidence of efficacy. Voclosporin, a rationally designed novel calcineurin inhibitor, exhibits a favorable safety profile, a strong correlation between pharmacokinetic and pharmacodynamic response, and a wide therapeutic window. The LUMINATE (Lux Uveitis Multicenter Investigation of a New Approach to TrEatment) clinical development program was initiated in 2007 to assess the safety and efficacy of voclosporin for the treatment, maintenance, and control of all forms of noninfectious uveitis. If LUMINATE is successful, voclosporin will become the first Food and Drug Administration-approved corticosteroid-sparing agent for this condition.Keywords: voclosporin, calcineurin inhibitors, LX211, LUMINATE trials, ophthalmic diseases, uveitis, ISA247 Eddy AngladeLauna J AspesletSidney L WeissDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2008, Iss Issue 4, Pp 693-702 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Eddy Anglade Launa J Aspeslet Sidney L Weiss A new agent for the treatment of noninfectious uveitis: rationale and design of three LUMINATE (Lux Uveitis Multicenter Investigation of a New Approach to Treatment) trials of steroid-sparing voclosporin
description	Eddy Anglade1, Launa J Aspeslet2, Sidney L Weiss11Lux Biosciences Inc., Jersey City, NJ, USA; 2Isotechnika Inc., Edmonton, AB, CanadaAbstract: Uveitis is an inflammatory, putative Th1-mediated autoimmune disease that affects various parts of the eye and is a leading cause of visual loss. Currently available therapies are burdened with toxicities and/or lack definitive evidence of efficacy. Voclosporin, a rationally designed novel calcineurin inhibitor, exhibits a favorable safety profile, a strong correlation between pharmacokinetic and pharmacodynamic response, and a wide therapeutic window. The LUMINATE (Lux Uveitis Multicenter Investigation of a New Approach to TrEatment) clinical development program was initiated in 2007 to assess the safety and efficacy of voclosporin for the treatment, maintenance, and control of all forms of noninfectious uveitis. If LUMINATE is successful, voclosporin will become the first Food and Drug Administration-approved corticosteroid-sparing agent for this condition.Keywords: voclosporin, calcineurin inhibitors, LX211, LUMINATE trials, ophthalmic diseases, uveitis, ISA247
format	article
author	Eddy Anglade Launa J Aspeslet Sidney L Weiss
author_facet	Eddy Anglade Launa J Aspeslet Sidney L Weiss
author_sort	Eddy Anglade
title	A new agent for the treatment of noninfectious uveitis: rationale and design of three LUMINATE (Lux Uveitis Multicenter Investigation of a New Approach to Treatment) trials of steroid-sparing voclosporin
title_short	A new agent for the treatment of noninfectious uveitis: rationale and design of three LUMINATE (Lux Uveitis Multicenter Investigation of a New Approach to Treatment) trials of steroid-sparing voclosporin
title_full	A new agent for the treatment of noninfectious uveitis: rationale and design of three LUMINATE (Lux Uveitis Multicenter Investigation of a New Approach to Treatment) trials of steroid-sparing voclosporin
title_fullStr	A new agent for the treatment of noninfectious uveitis: rationale and design of three LUMINATE (Lux Uveitis Multicenter Investigation of a New Approach to Treatment) trials of steroid-sparing voclosporin
title_full_unstemmed	A new agent for the treatment of noninfectious uveitis: rationale and design of three LUMINATE (Lux Uveitis Multicenter Investigation of a New Approach to Treatment) trials of steroid-sparing voclosporin
title_sort	new agent for the treatment of noninfectious uveitis: rationale and design of three luminate (lux uveitis multicenter investigation of a new approach to treatment) trials of steroid-sparing voclosporin
publisher	Dove Medical Press
publishDate	2008
url	https://doaj.org/article/801e6176649a4aa99f9d6d2511d1be30
work_keys_str_mv	AT eddyanglade anewagentforthetreatmentofnoninfectiousuveitisrationaleanddesignofthreeluminateluxuveitismulticenterinvestigationofanewapproachtotreatmenttrialsofsteroidsparingvoclosporin AT launajaspeslet anewagentforthetreatmentofnoninfectiousuveitisrationaleanddesignofthreeluminateluxuveitismulticenterinvestigationofanewapproachtotreatmenttrialsofsteroidsparingvoclosporin AT sidneylweiss anewagentforthetreatmentofnoninfectiousuveitisrationaleanddesignofthreeluminateluxuveitismulticenterinvestigationofanewapproachtotreatmenttrialsofsteroidsparingvoclosporin AT eddyanglade newagentforthetreatmentofnoninfectiousuveitisrationaleanddesignofthreeluminateluxuveitismulticenterinvestigationofanewapproachtotreatmenttrialsofsteroidsparingvoclosporin AT launajaspeslet newagentforthetreatmentofnoninfectiousuveitisrationaleanddesignofthreeluminateluxuveitismulticenterinvestigationofanewapproachtotreatmenttrialsofsteroidsparingvoclosporin AT sidneylweiss newagentforthetreatmentofnoninfectiousuveitisrationaleanddesignofthreeluminateluxuveitismulticenterinvestigationofanewapproachtotreatmenttrialsofsteroidsparingvoclosporin
_version_	1718400000384303104

A new agent for the treatment of noninfectious uveitis: rationale and design of three LUMINATE (Lux Uveitis Multicenter Investigation of a New Approach to Treatment) trials of steroid-sparing voclosporin

Ejemplares similares